The expiration of Eylea's patent is a significant event for Regeneron, leading to increased competition and pricing pressures, which negatively impacts revenue and profit margins. However, the potential growth from other drugs like Dupixent and Libtayo could offset some of these challenges, but the immediate impact is likely negative.